Resmetirom and semaglutide in MASH: fibrosis, dose, FDA

A 56-year-old man has had type 2 diabetes for nine years, weighs 104 kg and is 1.75 m tall. He takes metformin, atorvastatin 20 mg per day and clopidogrel since he had a coronary stent placed two years ago. At a routine exam, his transaminases were slightly above normal and the ultrasound showed a fatty liver. The FIB-4 index gave an intermediate value, and liver elastography suggested fibrosis between F2 and F3, with no signs of cirrhosis. He drinks little, about one beer a week. He asks whether there is a medicine for the liver. The scene is fictional and was written for teaching.

This text uses the case as a clinical reasoning scenario for students and health professionals. It covers two medicines approved in the United States for metabolic dysfunction-associated steatohepatitis, MASH, with moderate to advanced fibrosis: resmetirom and semaglutide 2.4 mg. The text explains how to estimate fibrosis, the indication, the dose, the interactions, what the studies showed and where the limits of the evidence are. It does not replace your institution's protocol or the local package insert. If you play the case of the day on NEXO, you will recognize the challenge: deciding with clues that arrive in sequence.

Key points

• Resmetirom (brand name Rezdiffra) is a thyroid hormone receptor beta agonist, indicated in the United States, together with diet and exercise, for adults with MASH without cirrhosis and fibrosis F2 to F3.
• The resmetirom dose depends on weight: 80 mg once a day below 100 kg and 100 mg once a day from 100 kg; with clopidogrel, the dose drops to 60 mg or 80 mg.
• Injectable semaglutide (brand name Wegovy) received the same indication in the United States in August 2025, with maintenance of 2.4 mg per week after a 16-week titration.
• Both American approvals are accelerated, based on improvement in biopsy, and depend on clinical outcome studies still in progress.
• In the European Union, Rezdiffra received conditional authorization on August 18, 2025.
• The regulatory dates in this text were checked with the FDA and the EMA on October 24, 2026.

Why this is a reasoning scenario

Metabolic dysfunction-associated steatotic liver disease, MASLD, has become the most common chronic liver disease in the world (Reinson and colleagues, 2026). Most people with a fatty liver will never have cirrhosis, but some develop inflammation, cell injury and fibrosis. It is fibrosis that weighs most on prognosis. For years, the answer for anyone asking for a medicine was just to change lifestyle. Now there are two options approved in the United States, and the question has become another one: who should receive which, and how to follow up.

The scenario is good for training because it forces you to put several clues together. You need to understand the diabetes, the weight, the alcohol, the statins, the antiplatelet agent, the FIB-4 and elastography results and what the patient expects. The post on signs, symptoms and history helps organize this collection, and the post on clinical decision-making reminds you that choosing between two medicines is a decision with a trade-off of risks.

What the scene teaches

The scene trains six habits. The first is to confirm that the cause is metabolic, and not alcohol or another liver disease. The second is to estimate fibrosis in stages, without jumping to biopsy. The third is to rule out decompensated cirrhosis, which changes management. The fourth is to review the medicines in use, because one of them interferes with the resmetirom dose. The fifth is to choose between resmetirom and semaglutide thinking about the whole patient. The sixth is to agree on how and when to reassess.

What is not at stake

The text does not discuss decompensated cirrhosis, transplantation, children or the dozens of medicines still in research. It also does not compare prices. The post on diagnostic uncertainty helps explain to the patient what is not yet known about medicines approved based on intermediate outcomes.

From steatosis to fibrosis: what MASH is

In 2023, the nomenclature changed. The term non-alcoholic fatty liver disease was replaced by metabolic dysfunction-associated steatotic liver disease, and non-alcoholic steatohepatitis, NASH, came to be called MASH (Kanwal et al., 2024). The MASLD definition excludes people who drink more than 20 g of alcohol per day, in the case of women, or more than 30 g per day, in the case of men (Kanwal et al., 2024). People with a cardiometabolic risk factor and consumption between 20 and 50 g per day in women or between 30 and 60 g per day in men fall into an intermediate category, called MetALD (Kanwal et al., 2024). For the patient in the scene, with one beer per week, the picture is MASLD.

Steatosis, inflammation and ballooning

On biopsy, MASH is defined by the presence of fat in the liver cells together with cell injury, called ballooning, and inflammation (Harrison et al., 2023). Fat alone is steatosis; when there is ballooning and inflammation, it is called steatohepatitis. Over time, inflammation stimulates the deposition of collagen, which forms fibrosis. Fibrosis is graded from F0, no fibrosis, to F4, which is cirrhosis; F2 is moderate fibrosis and F3, advanced fibrosis (EASL-EASD-EASO guideline, 2024).

Why fibrosis matters

The AASLD clinical practice guidance notes that hepatic decompensation was associated with higher all-cause mortality, with a hazard ratio of 6.8 after adjustment for several factors (Rinella et al., 2023). The BMJ Medicine review adds that MASLD increases the risk of cardiovascular events, chronic kidney disease and some cancers outside the liver (Reinson et al., 2026). In other words, the patient in the scene has two problems to treat: the liver and the heart. This weighs on the choice of drug.

The first treatment is still weight

The 2024 European guideline recommends weight loss with diet and behavior change to improve liver injury (EASL-EASD-EASO guideline, 2024). In adults with overweight, the goal is a sustained reduction of at least 5 percent of body weight to reduce liver fat, 7 to 10 percent to improve inflammation and at least 10 percent to improve fibrosis (EASL-EASD-EASO guideline, 2024). A review on incretin agonists reinforces that the basis of treatment is physical activity, aerobic and resistance exercise, weight loss and the Mediterranean diet (Singh et al., 2024). The two drugs in this text are indicated together with diet and exercise, and not in place of them (US prescribing information for Rezdiffra, 7/2026) (US prescribing information for Wegovy, 2/2026).

How to estimate fibrosis without a biopsy

Biopsy is still the reference standard in studies, but it is invasive and impractical for routine care. The guidelines propose a stepwise assessment with non-invasive tests (EASL-EASD-EASO guideline, 2024) (Rinella et al., 2023).

First step: FIB-4

The European guideline recommends starting with an established, non-patented blood score, such as the FIB-4 index (EASL-EASD-EASO guideline, 2024). It uses age, AST, ALT and platelets. The AASLD guidance uses a FIB-4 below 1.3 to identify people with a low probability of advanced fibrosis (Rinella et al., 2023). The same guidance recommends reassessing with FIB-4 every one or two years those with two or more metabolic risk factors, especially prediabetes or type 2 diabetes (Rinella et al., 2023). It also notes that test performance may be less reliable in people with diabetes (Rinella et al., 2023).

Second step: elastography or a specialized blood test

When FIB-4 does not rule out fibrosis, the next step is to measure liver stiffness by transient elastography or by magnetic resonance, or to use a blood test such as ELF (EASL-EASD-EASO guideline, 2024). The AASLD guidance describes ELF as a panel of three markers linked to liver matrix turnover: hyaluronic acid, tissue inhibitor of metalloproteinase 1 and N-terminal pro-collagen III peptide (Rinella and colleagues, 2023). The BMJ Medicine review summarizes that the European guideline recommends referral to a hepatologist when stiffness measured by transient elastography is 8.0 kPa or more, or when FIB-4 is 2.67 or more (Reinson and colleagues, 2026).

What the tests do not do

The predictive values of the tests depend on the cutoff chosen and on the frequency of fibrosis in the population tested (EASL-EASD-EASO guideline, 2024). An intermediate result calls for a repeat, another test or, sometimes, a biopsy. For the patient in the scene, elastography suggests F2 to F3, with no signs of cirrhosis, which matches the range of the two American indications (US label for Rezdiffra, 7/2026) (US label for Wegovy, 2/2026). Even so, it is worth checking platelets, albumin, bilirubin and the history of decompensation, because cirrhosis changes management. The post on differential diagnosis helps to remember other causes of altered transaminases, such as viral hepatitis, autoimmune disease, iron and medicines.

• Confirm that alcohol consumption is below the limits of the MASLD definition.
• Calculate FIB-4 with age, AST, ALT and platelets.
• If FIB-4 does not rule out fibrosis, perform elastography or a specialized blood test.
• Rule out other causes of liver disease.
• Look for signs of cirrhosis and decompensation.
• Refer to a hepatologist when the tests suggest advanced fibrosis.

Sources for the list: (EASL-EASD-EASO guideline, 2024) (Rinella and colleagues, 2023) (Reinson and colleagues, 2026).

Regulatory status: FDA and EMA

Resmetirom in the United States. The FDA approved Rezdiffra on March 14, 2024, under NDA 217785, as a new molecular entity, with priority review (Drugs@FDA, NDA 217785). Drugs@FDA lists label changes approved on December 19, 2025 and on July 24, 2026 (Drugs@FDA, NDA 217785). The label consulted was revised in July 2026 (US label for Rezdiffra, 7/2026). The indication is the treatment of adults with MASH without cirrhosis and with moderate to advanced fibrosis, consistent with stages F2 to F3, together with diet and exercise (US label for Rezdiffra, 7/2026). The approval is accelerated, based on improvement in MASH and fibrosis, and continued approval may depend on confirmation of clinical benefit in confirmatory studies (US label for Rezdiffra, 7/2026). The label calls for avoiding use in patients with decompensated cirrhosis (US label for Rezdiffra, 7/2026).

Semaglutide in the United States. Injectable Wegovy was already approved for weight control and reduction of cardiovascular risk. On August 15, 2025, the FDA approved an efficacy supplement, under NDA 215256, with the new indication for MASH (Drugs@FDA, NDA 215256). The most recent label listed is dated February 25, 2026 (Drugs@FDA, NDA 215256). The indication is the treatment of adults with MASH without cirrhosis and with moderate to advanced fibrosis, consistent with stages F2 to F3, also through accelerated approval (US label for Wegovy, 2/2026).

European Union. According to the EMA page, the committee for medicinal products for human use issued a positive opinion for Rezdiffra on June 19, 2025, and the marketing authorization was issued on August 18, 2025 (Rezdiffra page on the EMA). The page states that this is a conditional authorization, valid throughout the European Union (Rezdiffra page on the EMA). The Wegovy page on the EMA shows authorization since January 6, 2022 (Wegovy page on the EMA). On October 24, 2026, the summary of that page did not describe use in MASH, and therefore this text does not state that this indication exists in Europe.

Other countries. This text does not describe registration in other countries. Availability depends on the local agency.

What the studies showed

Resmetirom: the biopsy study

The registry study with biopsy, called Trial 1 in the label, included 888 adults with MASH and F2 or F3 fibrosis in the month 12 analysis: 294 on placebo, 298 on 80 mg and 296 on 100 mg (US label of Rezdiffra, 7/2026). The median age was 58 years, the median body mass index was 35 kg/m², and 68 percent had type 2 diabetes (US label of Rezdiffra, 7/2026). Each biopsy was read by two pathologists, and the label shows the results for each one (US label of Rezdiffra, 7/2026).

Resolution of MASH without worsening of fibrosis occurred in 13 and 9 percent on placebo, in 27 and 26 percent on 80 mg and in 36 and 24 percent on 100 mg, according to pathologists A and B (US label of Rezdiffra, 7/2026). Improvement in fibrosis by at least one stage without worsening of MASH occurred in 15 and 13 percent on placebo, in 23 and 23 percent on 80 mg and in 28 and 24 percent on 100 mg (US label of Rezdiffra, 7/2026). That is, about one in four patients improved their fibrosis on the drug, against a little more than one in eight on placebo.

Resmetirom: the safety study

A second phase 3 study, MAESTRO-NAFLD-1, assessed safety for 52 weeks in adults with disease presumed by non-invasive tests (Harrison et al., 2023). A total of 1143 patients were randomized, 972 of them in the three double-blind arms (Harrison et al., 2023). Mild or moderate diarrhea occurred in 23.5 to 31.2 percent on resmetirom against 13.8 percent on placebo, and nausea in 11.9 to 18.2 percent against 7.9 percent (Harrison et al., 2023). Diarrhea was more common in the first 12 weeks and lasted a median of 15 to 20 days (Harrison et al., 2023). The drug also reduced atherogenic lipids at week 24 (Harrison et al., 2023). A meta-analysis confirmed that diarrhea was more frequent in the first 12 weeks, with no significant difference after that (Suvarna et al., 2024).

Semaglutide: the biopsy study

In the week 72 analysis of the registry study, called Study 9 in the label, 800 adults with MASH and F2 or F3 fibrosis were included: 266 on placebo and 534 on semaglutide (US label of Wegovy, 2/2026). The median age was 57 years and 56 percent had type 2 diabetes (US label of Wegovy, 2/2026). Resolution of steatohepatitis without worsening of fibrosis occurred in 34 percent on placebo and 63 percent on semaglutide, a difference of 29 points (US label of Wegovy, 2/2026). Improvement in fibrosis without worsening of steatohepatitis occurred in 22 against 37 percent, a difference of 14 points (US label of Wegovy, 2/2026). Both outcomes together occurred in 16 against 33 percent (US label of Wegovy, 2/2026). Weight loss was 10.5 percent on semaglutide and 2 percent on placebo (US label of Wegovy, 2/2026).

The table summarizes the two biopsy studies, according to the US labels. The studies have different designs, durations and populations, and so the numbers should not be compared directly.

Drug and study	Duration	Patients	Resolution of MASH without worsening of fibrosis	Improvement in fibrosis without worsening of MASH	Source
Resmetirom 80 mg, Trial 1	12 months	298	27 and 26 percent (placebo 13 and 9)	23 and 23 percent (placebo 15 and 13)	(US label of Rezdiffra, 7/2026)
Resmetirom 100 mg, Trial 1	12 months	296	36 and 24 percent (placebo 13 and 9)	28 and 24 percent (placebo 15 and 13)	(US label of Rezdiffra, 7/2026)
Semaglutide 2.4 mg, Study 9	72 weeks	534	63 percent (placebo 34)	37 percent (placebo 22)	(US label of Wegovy, 2/2026)

Semaglutide in cirrhosis

Before the phase 3 study, a phase 2 study tested semaglutide 2.4 mg per week in 71 patients with compensated cirrhosis due to MASH (Loomba et al., 2023). After 48 weeks, there was no significant difference in improvement of fibrosis without worsening of steatohepatitis: 11 percent on semaglutide against 29 percent on placebo (Loomba et al., 2023). There was also no significant difference in resolution of steatohepatitis (Loomba et al., 2023). A 2025 review summarizes that, in this population, there was metabolic improvement, but no improvement in fibrosis on biopsy or imaging (Newsome and Loomba, 2025). This helps explain why the two US indications exclude cirrhosis.

How the drugs compare in the research

A network meta-analysis compared 26 interventions in biopsy-based MASH studies (Souza and colleagues, 2025). For improvement in fibrosis without worsening of MASH, several drugs ranked above placebo, among them resmetirom, tirzepatide and survodutide, with wide credible intervals (Souza and colleagues, 2025). Pegozafermin ranked at the top for this outcome (Souza and colleagues, 2025). A review on incretin agonists notes that tirzepatide and other dual agonists also showed promising biopsy results (Singh and colleagues, 2024). None of these data is a direct comparison between resmetirom and semaglutide, and these other drugs do not have the American indication for MASH described in this text.

How to read these numbers

Both drugs were approved based on biopsy outcomes, not on reduction of cirrhosis, transplant or death (US label for Rezdiffra, 7/2026) (US label for Wegovy, 2/2026). The studies that will measure these outcomes are ongoing. It is also worth noting that biopsy reading varies between pathologists, as shown by the difference between pathologists A and B in the resmetirom study (US label for Rezdiffra, 7/2026). For the patient in the scene, the honest message is that the drug increases the chance of liver improvement, but does not guarantee it, and that the long-term benefit is still being measured. The post about diagnostic pause reminds us to stop before turning an improvement on biopsy into a promise.

From choosing the drug to follow-up

Before prescribing, four questions change the approach: is there cirrhosis, how much does the patient weigh, which drugs does the patient use and what else needs treatment.

The resmetirom dose

The US label calls for 80 mg once a day for those weighing less than 100 kg and 100 mg once a day for those weighing 100 kg or more (US label for Rezdiffra, 7/2026). The tablet can be taken with or without food and must be swallowed whole (US label for Rezdiffra, 7/2026). With strong CYP2C8 inhibitors, such as gemfibrozil, use is not recommended (US label for Rezdiffra, 7/2026). With moderate CYP2C8 inhibitors, such as clopidogrel, the dose drops to 60 mg once a day below 100 kg or to 80 mg once a day from 100 kg (US label for Rezdiffra, 7/2026). The label does not list contraindications (US label for Rezdiffra, 7/2026).

Statins and other interactions

Resmetirom increases exposure to some statins. The label calls for limiting rosuvastatin and simvastatin to 20 mg per day and pravastatin and atorvastatin to 40 mg per day (US label for Rezdiffra, 7/2026). Resmetirom is also a weak CYP2C8 inhibitor (US label for Rezdiffra, 7/2026). The European guideline notes that statins can and should be used according to cardiovascular risk, including in chronic liver disease (EASL-EASD-EASO guideline, 2024).

Liver and gallbladder

The label describes a case of drug-induced autoimmune hepatitis, with ALT 58 times, AST 66 times and bilirubin 15 times above the upper limit of normal, which resolved after discontinuation (US label for Rezdiffra, 7/2026). For this reason, it calls for monitoring liver tests and watching for symptoms of liver injury (US label for Rezdiffra, 7/2026). Cholelithiasis, cholecystitis and gallstone pancreatitis were more frequent than with placebo, and treatment should be stopped in an acute gallbladder event (US label for Rezdiffra, 7/2026). Use should be avoided in Child-Pugh B or C hepatic impairment (US label for Rezdiffra, 7/2026).

The semaglutide dose

For MASH, the label for injectable Wegovy calls for escalation every 4 weeks: 0.25 mg, 0.5 mg, 1 mg and 1.7 mg per week in weeks 1 to 16, and then 2.4 mg per week as maintenance (US label for Wegovy, 2/2026). If 2.4 mg is not tolerated, the dose can be reduced to 1.7 mg, with a new attempt at 2.4 mg later (US label for Wegovy, 2/2026). The drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia type 2 (US label for Wegovy, 2/2026). The most common adverse events are gastrointestinal, such as nausea, diarrhea, vomiting and constipation (US label for Wegovy, 2/2026).

Applying it to the patient

The patient weighs 104 kg and takes clopidogrel, a moderate CYP2C8 inhibitor. If resmetirom is chosen, the dose would be 80 mg once a day, not 100 mg (US Rezdiffra label, 7/2026). Atorvastatin 20 mg is within the label limit (US Rezdiffra label, 7/2026). If semaglutide is chosen, the patient also gains the effect on weight and diabetes, and the Wegovy label includes cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight (US Wegovy label, 2/2026). The decision depends on tolerance, access, what the patient already takes for diabetes and what the patient prefers. The post on interprofessional clinical reasoning shows how hepatology, endocrinology, cardiology, pharmacy and nutrition build this plan together.

Follow-up

The plan includes liver tests at the start and during treatment, attention to abdominal pain and signs of gallbladder problems, review of interactions with every new medicine and reassessment of fibrosis with the same non-invasive tests over time (US Rezdiffra label, 7/2026) (EASL-EASD-EASO guideline, 2024). The patient also continues with the weight loss and exercise program, which remains the basis of treatment (EASL-EASD-EASO guideline, 2024).

How NEXO helps train this reasoning

In NEXO, the case of the day is fictional, with a real clinical presentation and up to six progressive clues, and you propose the diagnosis by searching for the ICD-10 code. MASH is a good exercise because alcohol, FIB-4, weight and an antiplatelet drug change management. The post on case-based learning explains why this format fixes knowledge.

Three exercises with cases

Change the weight. Say what the resmetirom dose would be if the patient weighed 92 kg and stayed on clopidogrel.

Change the liver. Say what to do if elastography and tests suggested cirrhosis with ascites.

Change the alcohol. Say how to classify the picture if the patient drank four beers a day.

The post on simulated consultations helps train the conversation about expectations and weight goals.

The limits on using the game are described on the NEXO Economy page. If you research teaching of clinical reasoning, the Researcher page explains how to get in touch. Professionals who write or review cases find information on Curator and Creators, and institutions can learn about the proposal on the partnerships page.

Frequently asked questions

Is resmetirom for people with cirrhosis?

The US indication is for MASH without cirrhosis, with fibrosis F2 to F3, and the label calls for avoiding use in decompensated cirrhosis (US Rezdiffra label, 7/2026).

What is the resmetirom dose?

80 mg per day below 100 kg and 100 mg per day from 100 kg, with a reduction if there is a moderate CYP2C8 inhibitor such as clopidogrel (US Rezdiffra label, 7/2026).

Is semaglutide for MASH the same as the one for weight control?

It is injectable Wegovy, with the same maintenance dose of 2.4 mg per week after titration (US Wegovy label, 2/2026).

Do I need a biopsy to start?

Guidelines propose a stepwise assessment with FIB-4 and elastography or another non-invasive test; biopsy is reserved for selected cases (EASL-EASD-EASO guideline, 2024) (Rinella et al., 2023).

Is resmetirom approved in Europe?

Yes. According to the EMA, it received conditional authorization on 18 August 2025 (Rezdiffra page on the EMA).

Final checklist

• I confirmed that alcohol consumption is compatible with MASLD.
• I ruled out other causes of liver disease.
• I estimated fibrosis in stages, with FIB-4 and elastography.
• I ruled out cirrhosis and decompensation.
• I checked the weight to set the resmetirom dose.
• I reviewed CYP2C8 inhibitors and the statin dose.
• I considered semaglutide with weight, diabetes and the heart also in mind.
• I combined liver tests, attention to the gallbladder and fibrosis reassessment.

Want to practice reasoning with progressive clues? Play the case of the day.

References

1. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. 2024. PMID 38869512.
2. European Medicines Agency. Rezdiffra | European Medicines Agency (EMA). Accessed on 10/24/2026. Official source.
3. European Medicines Agency. Wegovy | European Medicines Agency (EMA). Accessed on 10/24/2026. Official source.
4. Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023. PMID 37845512.
5. Kanwal F, Neuschwander-Tetri BA, Loomba R, et al. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024. PMID 38445559.
6. Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023. PMID 36934740.
7. Madrigal Pharmaceuticals. REZDIFFRA® (resmetirom) tablets, for oral use. Prescribing Information. Revised in 7/2026. Accessed on 10/24/2026. Official source.
8. Newsome PN, Loomba R. Therapeutic horizons in metabolic dysfunction-associated steatohepatitis. J Clin Invest. 2025. PMID 40590228.
9. Novo Nordisk. WEGOVY (semaglutide) injection, for subcutaneous use. Prescribing Information. Revised in 2/2026. Accessed on 10/24/2026. Official source.
10. Reinson T, Bilson J, Childs C, et al. Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults. BMJ Med. 2026. PMID 41947908.
11. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023. PMID 36727674.
12. Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol. 2024. PMID 39735270.
13. Souza M, Al-Sharif L, Antunes VLJ, et al. Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis. Hepatology. 2025. PMID 39903735.
14. Suvarna R, Shetty S, Pappachan JM. Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Sci Rep. 2024. PMID 39187533.
15. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. NDA 217785, Rezdiffra. Accessed on 10/24/2026. Official source.
16. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. NDA 215256, Wegovy. Accessed on 10/24/2026. Official source.